NCT06931080 - Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients | Biotech Hunter

Enrollment

630

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

DRUG

EB-1020 (Centanafadine) 164.4 mg

164.4 mg, capsule, oral, once daily, for 6 weeks

DRUG

EB-1020 (Centanafadine) 328.8 mg

328.8 mg, capsule, oral, once daily, for 6 weeks

DRUG

Placebo

Placebo, capsule, oral, once daily, for 6 weeks

Trial Locations (1)

RECRUITING

Maynds Tower Mental Clinic, Tokyo